- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01271348
Study of Etoricoxib for the Treatment of Muscle Pain and Inflammation Induced by Eccentric Exercise
October 31, 2011 updated by: X-pert Med GmbH
Multiple-dose, Randomized, Double Blinded, Placebo-controlled, Cross Over Study of Etoricoxib for the Treatment of Muscle Pain and Inflammation Induced by Eccentric Exercise
Comparison of the effect of etoricoxib to placebo on muscle pain caused by eccentric contractions
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Jena, Germany, 07745
- X-pert Med GmbH
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 68 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed and dated informed consent prior to participation
- Subjects in good health as determined by the Investigator
- Age 18-40 or 50-70
- BMI > 20 and < 30
- Pain in the target muscle (thigh) during muscle contraction of at least 5 on an 11 point categorical pain rating scale
- Willing to abstain from any physical therapy, hard physical work, exercise or sauna during the study treatment periods (Screening to Final Visit)
- For females, subjects of childbearing potential (including peri-menopausal women who have had a menstrual period within 1 year) must be using appropriate birth control (defined as a method which results in a low failure rate, i.e., less than 1% per year when used consistently and correctly, such as implants, injectables, some intrauterine contraceptive devices (IUDs), sexual abstinence, or a vasectomized partner). Oral contraceptive medications are not allowed in this study. Female subjects, who are surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) are allowed for participation
Exclusion Criteria:
- Participation in another clinical study within the last 30 days and during the study
- Subjects who are inmates of psychiatric wards, prisons, or other state institutions
- Investigator or any other team member involved directly or indirectly in the conduct of the clinical study
- Pregnancy or lactation
- Alcohol or drug abuse
- Malignancy within the past 2 years with the exception of in situ removal of basal cell carcinoma
- Known hypersensitivity to etoricoxib or other NSAID´s including Cox-2, or any of their excipients
- Bronchospasm, acute rhinitis, nasal congestion, angioneurotic edema, urticaria or allergic reactions after taking aspirin or other NSAIDs including Cox-2 inhibitors
- Major traumatic lesions (e.g. fracture, tendon or muscle ruptures) of the musculo-sceletal system of the lower limbs
- Pain conditions which might interfere with pain rating during the study, e.g. neuropathic pain
- Significant neurological or psychiatric symptoms resulting in disorientation, memory impairment, or inability to report accurately (e.g. depressive disorders, Alzheimer's disease, schizophrenia or other psychosis), that in the investigator's opinion may affect efficacy or safety assessments or may compromise subject safety during the study
- Heart failure (NYHA II-IV)
- Long term blood pressure > 140/90 mm Hg without adequate treatment
- Peripheral arterial disease, coronary heart disease and/or cerebrovascular disease
- History of stroke or myocardial infarction
- Clinically relevant ECG changes
- Estimated creatinine clearance < 60 ml/min
- Liver dysfunction (e.g. defined by ALT and/or AST levels above upper limit of normal range)
- Coagulopathy or bleeding diathesis, or concomitant use of anticoagulants including low dose aspirin
- History of pancreatitis, peptic ulcers or gastrointestinal bleedings
- Inflammatory GI disease (e.g. M. Crohn, colitis ulcerosa)
- Any other analgesic therapy including cough and cold drugs containing analgesic properties as well as any other substance used for the treatment of pain during the study observation period (Screening to final Visit)
- Any other drug that might alter pain perception like CNS active drugs
- Statins within 3 months of screening and throughout the study
- Oral anticonceptives
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo tablet
|
Placebo tablet, q.d.
|
Active Comparator: Etoricoxib
|
Etoricoxib film tablet, 90 mg, q.d.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pain during muscle contraction
Time Frame: 7 days
|
7 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Matthias Rother, M.D., Director Clinical Operations
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2011
Primary Completion (Actual)
October 1, 2011
Study Completion (Actual)
October 1, 2011
Study Registration Dates
First Submitted
January 5, 2011
First Submitted That Met QC Criteria
January 5, 2011
First Posted (Estimate)
January 6, 2011
Study Record Updates
Last Update Posted (Estimate)
November 1, 2011
Last Update Submitted That Met QC Criteria
October 31, 2011
Last Verified
October 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Musculoskeletal Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Musculoskeletal Pain
- Myalgia
- Inflammation
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Cyclooxygenase 2 Inhibitors
- Etoricoxib
Other Study ID Numbers
- XPM-032
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Muscle Pain
-
University of Texas Southwestern Medical CenterAbhimanyu Garg; Prishant Mishra; Jimin RenCompletedMuscle Weakness | Muscle Cramp | Muscle Stiffness | Statin-related Muscle Pain | Muscle AchesUnited States
-
University of North Carolina, Chapel HillNational Institutes of Health (NIH); North Carolina Translational and Clinical...CompletedMuscle Pain | Muscle Weakness | Muscle Tone Increased | Hamstring InjuryUnited States
-
Christian Müller, MDUniversity Hospital Inselspital, Berne; Medical University Innsbruck; University... and other collaboratorsRecruitingMuscle Weakness | Muscle Atrophy | Muscle Spasticity | Muscle Cramp | Muscle Soreness | Muscle Damage | Myopathy | Muscle InjurySwitzerland, Austria
-
University of SurreyCompletedMuscle Soreness | Muscle Strength | Muscle DamageUnited Kingdom
-
McNeil Consumer & Specialty Pharmaceuticals, a...Completed
-
MedtronicCompletedChronic Pain | Spasticity, MuscleBelgium, Spain, Czechia, France, Netherlands, Slovenia, Switzerland, United Kingdom
-
Sun Pharma Advanced Research Company LimitedWithdrawnAcute Muscle Pain
-
Health Education Research Foundation (HERF)CompletedNeck Pain | Trigger Point Pain, Myofascial | Muscle Tightness | Neck Muscle Issue | NeckachePakistan
-
Mucos Pharma GmbH & Co. KGCompletedMuscle Soreness | Muscle Injury | Exercise Induced Muscle DamageGermany
-
Eisai Inc.Eisai Co., Ltd.Completed
Clinical Trials on Etoricoxib
-
Organon and CoCompleted
-
Organon and CoCompleted
-
Organon and CoCompleted
-
Organon and CoCompleted
-
Radboud University Medical CenterCompletedOssification, HeterotopicNetherlands
-
Organon and CoCompleted
-
Clinica Virgen MilagrosaMerck Sharp & Dohme LLCTerminatedSoft Tissue Injuries of the Shoulder | Tenosynovitis and Bursitis Affecting the ShoulderPeru
-
University of Erlangen-Nürnberg Medical SchoolMerck Sharp & Dohme LLC; Rush University Medical Center; HELIOS Kliniken GmbHTerminatedPain | Postoperative Pain | Osteoarthritis, HipGermany
-
Núcleo de Estudos em Esportes e Ortopedia, BrazilMerck Sharp & Dohme LLCUnknownSprains and Strains | ContusionsBrazil
-
Organon and CoCompletedAcute Pain Following a Total Abdominal Hysterectomy